Table 3: DC-based vaccines clinical trial.

DC-based vaccinesPatients enrolledPhase of the studyClinical resultsReferences

MUC1 peptide-loaded DC12 with resected pancreatic and biliary cancerI/II4 of the 12 patients followed for over four years were alive[139]

DC transfected with MUC1 cDNA10 with advanced breast, pancreatic, or papillary cancerI/II4 patients showed a 2- to 10-fold increase in the frequency of MUC1-specific IFN-gamma-secreting CD8+ T cells.[140]

mRNA CEA-loaded DC3 with resected PCPilot studyThe immunizations were well tolerated without evidence of adverse events. All patients were alive without evidence of disease at more than 30 months from the original diagnosis.[141]

Peptides (mutant p53- and k-ras-loaded DC39 patients with several types of cancer (lung, breast, pancreatic, ovarian, colon, others)I10 (26%) of 38 patients had detectable CTL against mutant p53 or K-ras, and 2 patients were positive for CTL at baseline. Positive IFN-γ responses occurred in 16 patients (42%) after vaccination, whereas 4 patients had positive IFN-γ reaction before vaccination. Cellular immunity to mutant p53 and K-ras oncopeptides is associated with longer survival.[142]

DC engineered (secreting IL-2)17 patients with several types of cancer (3 metastatic pancreatic, 5 colorectal, 9 liver, cancer) Pilot studyTreatment was well tolerated. DC treatment induced a marked increase of infiltrating CD8+ T lymphocytes in three of 11 tumor biopsies analyzed. A partial response was observed in one patient with pancreatic carcinoma.[143]